6932.TWO Mercury Biopharmaceutical Corporation

Healthcare Drug Manufacturers - Specialty & Generic Taiwan OTC Exchange
5.15 TWD
Close of Nov 5, 2026
4.71 12.20
Market cap
TWD 2.20B
P/E
-
P/B
11.61x
ROE
-30.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6932.TWO undervalued?

Graham number

The Graham number of Mercury Biopharmaceutical Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mercury Biopharmaceutical Corporation fundamental analysis

No fundamental analysis for Mercury Biopharmaceutical Corporation yet.

Mercury Biopharmaceutical Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mercury Biopharmaceutical Corporation

Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development. It also offers formulat…

Full company profile